Work

PB1578 Anti-platelet factor 4 (PF4) antibody levels increase with coronary artery disease severity: results from an angiographically controlled study

Year: 2026

Type: conference-abstract

Abstract: Platelet-activating antibodies targeting platelet factor 4 (anti-PF4) are responsible for severe prothrombotic disorders e.g. heparin-induced thrombocytopenia (HIT) and virus/vaccine-induced immune thrombocytopenia and thrombosis (VITT). In contrast, non-platelet-activating anti-PF4 antibodies have been described in association with pro-inflammatory conditions. Coronary artery disease (CAD) is characterized by chronic inflammation and a prothrombotic milieu. It is unclear, whether non-platelet-activating anti-PF4 antibodies are associated with CAD severity and if they play a role in CAD pathogenesis.

Source: Research and Practice in Thrombosis and Haemostasis

DOI: 10.1016/j.rpth.2026.104440

Authors: Giulio Luigi Bonisoli, Gerardo Musuraca, Nicola Osti, Jan Wesche, Jessica Fuhrmann, Annalisa Castagna, Patrizia Pattini, Gabriele Mango, Cathie Brocco, Carlo Angheben, Jessica Pizzini, Maddalena Saghir, Adriano Anesi, Antonio Ferro, Simonetta Friso, Andreas Greinacher, Nicola Martinelli, Thomas Thiele

Institutions: University of Verona, Universitätsmedizin Greifswald

Language: English

Topic: Heparin-Induced Thrombocytopenia and Thrombosis

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,250

OpenAlex ID: W7220474366

Cites:

Cited by:

Related to: 10